Dean Y. Li

Dean Y. Li, Executive VP & President, MRL at Merck & Co., Inc. (25 filings) and a director of Recursion Pharmaceuticals, Inc. (44), has filed 69 disclosures since March 2, 2021, including 9 sales worth EUR 5,228,240 in total with a median of EUR 269,851. There is no purchase. The three largest took place at Merck: EUR 1,712,032 on February 9, 2024, EUR 1,516,471 on February 4, 2026 and EUR 1,010,449 on February 10, 2026.

The record also holds 39 share grants, 12 filings of another kind and 9 option exercises. The busiest year is 2021 with 25 filings, against 6 to 10 a year afterwards. Nine filings, 2 of them sales, fall in the last twelve months.

At Recursion, Blake Borgeson, Christopher Gibson and Tina Marriott Larson each have 6 trades within 30 days of Li's; at Merck, Caroline Litchfield and David Michael Williams have 3 each. All go in the same direction. Filings are published a median of 2 days after the trade.